Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Официальное название

An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Обзор

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.

Вмешательства

• Препарат Cyclophosphamide
  Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
• Препарат Sirolimus
  Sirolimus 4 mg, PO, days 1-28

Первичные конечные точки

• Percentage of patients that respond to treatment [Срок оценки: Patients will be followed for response until progression or up to 2 Years]

Вторичные конечные точки (3)

• The number of patients that experience toxicity [Срок оценки: Patients are followed for toxicity up to 30 days after the last dose of study drug]
• Median overall survival time [Срок оценки: Patients will be followed until death or up to 2 years]
• Median progression free survival time [Срок оценки: Patients will be followed for response until progression or up to 2 Years]

Критерии участия

Критерии включения

• Histologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment
• Measurable disease (>10 mm) and have progression of disease based on RECIST criteria. Previously irradiated tumor lesions are not considered measurable unless they have progressed since radiation.
• Previous failure of Iodine-131 (131I) therapy or not candidates to receive 131I as assessed by treating physician.
• Age ≥ 18 years
• ECOG (Eastern Cooperative Oncology Group) performance status 0-2
• Life expectance of ≥ 12 weeks
• 131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)
• Adequate organ and marrow function
• Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
• Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
• Willingness and ability to comply with scheduled visits, treatment plans, including willingness to take study medication, laboratory tests, and other study procedures

Критерии исключения

• Inability to obtain Foundation One testing on archival tissue, or, lack of previous Next Generation Sequencing
• Chemotherapy, tyrosine kinase inhibitor, or radiation therapy within 4 weeks
• Prior experimental therapy within 4 weeks of planned start of this trial
• 131I therapy within 24 weeks before entry (4 weeks if negative post-treatment scan)
• Previous treatment with an mTOR inhibitor
• Patients who are currently receiving treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein that cannot be discontinued at least one week prior to the start of treatment with Cyclophosphamide and Sirolimus
• Impairment of GI (gastrointestinal) function or GI disease that may significantly alter the absorption of study medications (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection) including dependence on a G-Tube for administration of medications.
• A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment
• Patients with known sensitivities to either cyclophosphamide and/or sirolimus
• Patients with known urinary outflow obstruction
• Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
• Patients (male and female) having procreative potential who are not willing or not able to use adequate contraception or practicing abstinence
• Women who are pregnant or breast-feeding
• Patients residing in prison

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 1 центр

• University of Michigan Cancer Center — Ann Arbor

Идентификаторы

NCT: NCT03099356 · UMCC 2017.013 · HUM00126559

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗